Successful tocilizumab treatment for rapidly progressive interstitial lung disease with anti-MDA5-positive juvenile dermatomyositis: a case report and literature review
Tocilizumab may serve as an effective adjunctive treatment option for patients with refractory anti-MDA5-positive JDM complicated by RP-ILD who do not respond to conventional intensive immunosuppressive therapies.
Authors
- Lingzhi Qiu
- Zhidan Fan (ORCID: https://orcid.org/0009-0008-2473-2480)
- Le Ma (ORCID: https://orcid.org/0000-0001-7592-9779)
- Xiaoyan Shao (ORCID: https://orcid.org/0000-0003-3014-6820)
- Haiguo Yu (ORCID: https://orcid.org/0000-0002-1115-238X)
Institutions
- Second Affiliated Hospital of Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Pediatrics
- Published
- 2024-11-27
- DOI
- https://doi.org/10.3389/fped.2024.1497168
- Citations
- 2
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- National Natural Science Foundation of China